• GH Research published full Phase 2a postpartum depression results for inhaled mebufotenin, previously released only in summary form.
• The small open-label study showed rapid symptom relief following a single-day treatment, with benefits sustained through Day 8.
• Participants also reported better maternal functioning, supporting potential differentiation in a high-need segment.
• Safety profile was favorable, with no serious adverse events; breast-milk findings pointed to only a brief pause in breastfeeding.
• Separate Phase 2b treatment-resistant depression data are scheduled for oral presentation at CINP 2026 on June 27-28, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GH Research plc published the original content used to generate this news brief on June 04, 2026, and is solely responsible for the information contained therein.